Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

185.15USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$185.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,721,240
52-wk High
$201.23
52-wk Low
$163.31

Select another date:

Fri, Jun 15 2018

Photo

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH, June 15 Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original. Switching from

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.

UPDATE 2-FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

* Mylan shares up 5.2 pct, Amgen down 1.7 pct after market (Adds analyst comment, updates shares)

U.S. FDA approves Amgen drug for prevention of migraines

Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention

* NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION

Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

* Shares of Amgen, JNJ fall in afternoon trading (Adds analyst comments, updates shares)

Select another date: